Three details:
1. Nanovis’ nanotechnology-based spinal implants are designed to help surgeons and hospitals achieve improved fixation and infection outcomes.
2. Nanovis is working on developing a bactericidal capability for its spinal technologies as well as technology to treat and prevent localized infections.
3. “Sales of our fixation technologies are increasing rapidly, and our next generation technologies are killing virulent and deadly antimicrobial resistant bacteria while still growing bone,” said Matt Hedrick, CEO of Nanovis. “This creates tremendous urgency for us to safely and responsibly bring these technologies to patients who can benefit from them. Many of our customers work with Nanovis not only because of our fixation technology enhanced spinal implants but also to help support this vision.”
More articles on devices and implants:
Minimally invasive surgical instruments market to reach $38.3B by 2025 due to spine surgery demands
Medtronic, Johnson & Johnson among active players in $410B medical devices market
Top orthopedic company reports 13% market share drop in one year, but keeps No. 1 spot: 10 key statistics
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.